Approval Status
Approved September 1997

Treatment for

Cardiovascular / Cardiology , Diabetes / Endocrinology

Neurex Corporation received marketing clearance from the U.S. Food and Drug Administration (FDA) for Corlopam. Corlopam is an intervenous treatment for severe high blood pressure. Corlopam is administered in the hospital over a six-hour to 48-hour period to relieve severe hypertensive spikes.

Corlopam Drug Information

The Corlopam drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top